Abstract: The invention relates to PD-1:PD-L1 non-blocking immunoconjugates comprising an IL-2 polypeptide providing a biased signal to the dimeric IL-2 receptor, and a PD-1 targeting domain, and their use for treating cancer.

Abstract: The invention relates to anti-PD-1 antibody binding domains which do not disrupt signaling between PD1 and PD-L1, and immunoconjugates comprising same targeting an immunomodulatory domain to PD-1-expressing cells.

Abstract: The present invention relates to immune-stimulating IL-2 fusion proteins comprising antibodies joined to human interleukin-2 (hIL-2). The invention more specifically relates to humanized monoclonal antibodies or fragments thereof joined to hIL-2 or variants thereof and displaying a unique capability of preferentially stimulating cytotoxic T cells and NK cells compared to Treg cells. Furthermore, the invention relates to in vitro and in vivo therapeutic applications of the IL-2 fusion proteins, in particular as an immunotherapy in the treatment of cancer.